PINE BROOK, N.J., March 28, 2011 /PRNewswire/ — Diopsys, Inc.
has launched the new Diopsys® NOVA-DN VEP Vision Testing System
to help optometrists and ophthalmologists detect optic nerve
disease, including glaucoma and other neuro-visual disorders.
Glaucoma is the second leading cause of blindness in the world,
reports the World Health Organization. According to Prevent
Blindness America, glaucoma is often called the “sneak thief of
sight” because half of all patients who have it do not know it.
Many optic nerve disorders, such as glaucoma and ischemic
optic neuropathy, are asymptomatic since central vision may not be
affected until later stages of the disease. Also, diagnosis and
management of optic nerve disorders are often based on structural
or visual field tests which are limited in their ability to detect
disease early.
The Diopsys® NOVA-DN allows clinicians to objectively assess
optic nerve disease earlier than traditional vision tests because
it uses Visual Evoked Potential (VEP) technology and proprietary
software to evaluate the entire vision system from the eye to the
visual cortex. “VEP is an objective, functional test that can help
discriminate between healthy and glaucomatous eyes,” says Alberto
Gonzalez Garcia, M.D., neuro-ophthalmologist and Research Director
at Diopsys, Inc. Optometrists and ophthalmologists may use VEP in
addition to traditional testing methods to enhance diagnosis and
treatment.
The Diopsys® NOVA-DN records the electrical response of a
patient’s entire vision system and provides easy-to-read reports
that give the doctor a simple way to evaluate optic nerve function.
Physicians are able to compare tests over time to track
disease progression.
Dr. Fran Bucciero of Family Vision Care in Springfield, NJ, one
of the first eye care professionals to have the device in his
office says, “I’ve been using the Diopsys® NOVA-DN in my
practice to help me diagnose glaucoma
‘/>”/>
